News
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
Shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX), a clinical-stage biotech, rose 16.3% in September, according to data from S&P Global Market Intelligence. It looks like investors....
This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheap
What's the best U.S. marijuana stock on the market right now?Including only the U.S. in the question excludes several of the top candidates, such as U.K.-based GW Pharmaceuticals (NASDAQ: GWPH)....
Why Celldex Therapeutics, Inc. Jumped Higher Today
Celldex Therapeutics (NASDAQ: CLDX) closed on Monday up 12.8%, with no apparent news to justify the double-digit gain by the biotech company.The move follows an 8.1% jump on Friday. Sometimes,....
This Marijuana Stock Is On an 8-Day Losing Streak -- Is It Time to Buy?
Over the trailing year, there's arguably been no better-performing industry than marijuana and marijuana stocks. A majority of pot stocks have moved significantly higher over the past year, with a....
Of the 14 Largest Marijuana Stocks, Only These 2 Are Down Over the Past Year
The stock market has been on a tear since hitting a trough in March 2009, but in recent years it's marijuana stocks that have headed to the front of the class, so to speak. Back in June, we looked....
Why This Marijuana Stock Crashed 18.5% in August
Arizona's attorney general is suing Insys Therapeutics (NASDAQ: INSY) over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company's shares to tumble 18.5% in August,....
94% of Americans Support Legalizing Medical Marijuana, but Not Congress
When it comes to the fastest, most consistently growing industries in the U.S. right now, legal marijuana is near the top of the list. Investment firm Cowen & Co. has predicted that U.S. legal....
3 Top Healthcare Stocks to Buy Now
It's been a good year for healthcare stocks in general, but a handful of quality companies haven't been swept upward with the rest of the sector. Allergan plc (NYSE: AGN) and CVS Health Corp.....
3 Top Biotech Stocks Under $10
Cheap and junk don't have to go hand in hand. Sometimes, items that are inexpensive could still have tremendous potential for their values to increase. That can be true with anything you buy --....
3 Game-Changing Small-Cap Healthcare Stocks
The ability to shake up patient treatment could mean big bucks for Tetraphase Pharmaceuticals (NASDAQ: TTPH), NovoCure (NASDAQ: NVCR), and Exact Sciences (NASDAQ: EXAS). Should you be buying shares in
3 Beaten-Up Biotech Stocks: Are They Bargains?
The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15% so far this year, without any help from Celldex Therapeutics, Inc. (NASDAQ: CLDX), Agenus Inc. (NASDAQ: AGEN), or
This Struggling Marijuana Stock Finally Launched Its Highly Anticipated Drug
If you look around, chances are you won't find many marijuana stocks struggling. In fact, over the trailing one-year period, 12 out of 13 pot stocks with a market cap above $200 million had risen
3 Marijuana Stocks That Could Make You the Most Money in the 2nd Half of 2017
For investors who enjoyed the huge run of marijuana stocks last year, the first half of 2017 probably hasn't been as exciting. Several of the largest marijuana stocks haven't performed all that great
This Marijuana Stock Skyrocketed Last Week, While 3 Others Plunged
When it comes to the market's top-performing stocks, you'd have a hard time topping marijuana stocks over the trailing year. A majority of pot stocks over the past 12 months have at least doubled in
Why Tetraphase Pharmaceuticals Fell 11.7% Today
After reporting positive trial results for its lead product candidate on July 25, Tetraphase Pharmaceuticals (NASDAQ: TTPH) announced a $60 million share offering today that will dilute investors, and
Here's Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today
Shares of clinical-stage biopharma Tetraphase Pharmaceuticals (NASDAQ: TTPH) soared nearly 27% today after the company announced positive top-line results for a phase 3 trial evaluating its lead
Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics
Celldex Therapeutics (NASDAQ: CLDX) and Juno Therapeutics (NASDAQ: JUNO) are both once-promising clinical-stage biotechs that have fallen on extremely hard times of late. Over the past two and half
5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there's the third type of marijuana stock: the
OncoGenex kurz vor MEGA-FUSION!
Liebe Leser,
ein bisher eher unscheinbarer Wert sorgt am Dienstag für viel Aufsehen an der Börse. OncoGenex und Achieve Life gaben kürzlich bekannt, fusionieren zu wollen und beflügeln damit die....
Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
NEW YORK, May 21, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today presented....
Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index
NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has....
Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results
NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial....
Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock
NEW YORK, April 16, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its....
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock
NEW YORK, April 10, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing....
Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock
NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it is....